ASCO Preview: Top Five Picks From The Abstract Release
The oncology conference promises some significant data readouts across pancreatic, breast and lung cancers, lymphoma, myeloma and more.
Scrip - May 22, 2026

Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition
Plus deals involving Incyte/Genesis Molecular AI and Edison Scientific, Jupiter/PharmAla, Abeona/Angeles Therapeutics, Daewoong/Innovo, GSK/CTTQ and more.
Scrip - May 22, 2026

Bayer Raises Its Cell And Gene Therapy Bet As Others Fold
The sector has seen multiple setbacks, with some big pharmas heading for the exits, but the German major believes its heavy investments in the space will ultimately pay dividends.
Scrip - May 22, 2026

Biogen, Denali Discontinue BIIB122 Development In Idiopathic Parkinson’s After Phase IIb Miss
Biogen and Denali’s decision to discontinue BIIB122 in idiopathic Parkinson’s disease after a failed Phase IIb study shifts focus toward genetically defined LRRK2 patient subsets and other late-stage neuroscience pipeline catalysts.
Scrip - May 22, 2026

The 30-Day Bet: Serum Institute Plans Rapid Response To Ebola Outbreak
As Serum Institute aims to get an Oxford-partnered vaccine out at unprecedented speed, the question is whether industry players like Serum, Mapp, Hyundai and others can move faster with vaccines or experimental drugs than Ebola’s Bundibugyo species?
Scrip - May 22, 2026

ASCO Preview: BioNTech, Innovent/Takeda Vie For Top IO Combo Responses In 1L NSCLC
BioNTech’s pumitamig demonstrated an ORR of 77.3% in first-line NSCLC regardless of PD-L1 status, while Innovent/Takeda’s IBI363 pushed the rate to 86.4% in the non-PD-L1-high population, ASCO abstracts show.
Scrip - May 22, 2026

New Data Show Medtronic’s Altaviva Offers ‘Greater Flexibility’ For Treating Urge Incontinence
Medtronic presented 24-month data from its Altaviva TITAN 2 pivotal study at the 2026 American Urological Association Annual Meeting in DC. Medtronic says Altaviva, a small device implanted just below the skin near the ankle, offers relief for millions with urge urinary incontinence.
Medtech Insight - May 22, 2026

MiniMed Study Finds Sensor Choice Has Little Impact On Glycemic Outcomes With 780G System
A head-to-head crossover trial and real-world data from more than 20,000 patients point to the same conclusion: in automated insulin delivery, the algorithm matters more than the sensor. MiniMed's 780G system is now backed by mounting evidence – and a fresh Nasdaq listing.
Medtech Insight - May 22, 2026

Abiomed’s Latest Impella Recall Can’t Be Fixed by Swapping Units
The FDA has issued an early alert on Automated Impella Controllers from Johnson & Johnson subsidiary Abiomed because the devices may suddenly restart. This is the latest in a series of recalls for the heart pump specialists.
Medtech Insight - May 22, 2026

EMA Decision For Boehringer’s Jascayd Paves Way For New IPF and PPF Treatment In Europe
Jascayd, for treating adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, is among eight new medicines that the European Medicines Agency recommended for pan-EU marketing approval this week.
Pink Sheet - May 22, 2026

EU Notified Bodies See A Weakened System While Industry Counts On Timeline Predictability
EU notified bodies will be given maximum turnaround times for medtech file processing once the European Commission’s binding EU implementing regulation comes into force. Notified bodies think it does not give due attention to their place in the care delivery system.
Medtech Insight - May 22, 2026

Personalis Wins Fourth Medicare Coverage For NeXT Personal MRD Test In Neoadjuvant Breast Cancer
Medicare will now reimburse Personalis's ultrasensitive ctDNA test for monitoring treatment response before surgery in Stage II–III triple-negative and HER2-positive breast cancer patients, extending the test's coverage footprint deeper into the treatment pathway.
Medtech Insight - May 22, 2026

MHRA Outlines Plans For Medical Device CE Mark Recognition
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
HBW Insight - May 22, 2026

People On The Move: Appointments at Cooper, Opella, Chiesi
A round up of the latest people moves: Cooper Consumer Health names Italy head and Iberia marketing lead; Opella appoints people head for Europe and LatAm; and Chiesi elects chair.
HBW Insight - May 22, 2026

FDA Will Miss May Allergen Labeling Rule Deadline – OCC Deputy Director
Deputy Director of the US FDA's Office of Cosmetics and Colors provided a MoCRA update during IBA's Spring 2026 Cosmetics Convergence conference in New York May 21.
HBW Insight - May 22, 2026

US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry/marketplace news: Congress proposes adding supplements to HSA/FSAs; acting FDA foods program chief familiar to industry; PRE study guidance for formula industry; higher costs not new to industry; and ‘fundamental reset’ in longevity wellness.
HBW Insight - May 22, 2026

CHMP Endorses Another Ranibizumab For Lupin
At its latest meeting, the EMA’s CHMP has endorsed a further biosimilar ranibizumab rival to Lucentis from Lupin. Meanwhile, Celltrion has withdrawn a filing for an infliximab product.
Generics Bulletin - May 22, 2026

Formycon Launches Pre-Filled Eylea Biosimilars In Europe
With a US launch window locked in for Q4 2026 and Europe already live, Formycon is converting years of development and deal-making into commercial momentum.
Generics Bulletin - May 22, 2026

Is AI The Catalyst For Global Biosimilars Development? IQVIA and Kexing Think So
As AI takes center stage, a new extended partnership between Kexing Biopharm and IQVIA is working to further global biosimilars development.
Generics Bulletin - May 22, 2026

Sawai Seeks Margin Protection Through Scale And Reliability
Sawai is positioning stable supply, new launches and expanded capacity as profit levers under Japan’s tougher generics pricing regime, even as mature products face pressure.
Generics Bulletin - May 22, 2026

Rising Leaders: Kyowa Kirin On Achieving Success Through Embracing Kabegoe
Kyowa Kirin's Céline Rhême, cluster general manager for emerging markets, champions the company's Kabegoe mindset — breaking barriers to expand access to rare disease therapies across nearly 30 markets.
In Vivo - May 23, 2026

Execs On The Move: April 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - May 23, 2026